Scott Klarenbach

Scott Klarenbach

Auto-generated profile, based on publicly available information

Scott Klarenbach

University of Alberta

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2015 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
MTMarcello Tonelli
Marcello Tonelli
NWNatasha Wiebe
Natasha Wiebe
MFMartin Fortin
Martin Fortin
BGBruce Guthrie
Bruce Guthrie
BHBrenda R Hemmelgarn
Brenda R Hemmelgarn
FNFor The Alberta Kidney Disease Network
For The Alberta Kidney Disease Network
Multimorbidity is common and associated with poor clinical outcomes and high health care costs. Administrative data are a promising tool for studying the epidemiology of multimorbidity. Our goal was to derive and apply a new scheme for using administrative data to identify the presence of chronic conditions and multimorbidity. We identified validated algorithms that use ICD-9 CM/ICD-10 data to ascertain the presence or absence of 40 morbidities. Algorithms with both positive predictive value and sensitivity ≥70% were graded as “high validity”; those with positive predictive value ≥70% and sensitivity <70% were graded as “moderate validity”. To show proof of concept, we applied identified algorithms with high to moderate validity to inpatient and outpatient claims and utilization data from 574,409 people residing in Edmonton, Canada during the 2008/2009 fiscal year. Of the 40 morbidities, we identified 30 that could be identified with high to moderate validity. Approximately one quarter of participants had identified multimorbidity (2 or more conditions), one quarter had a single identified morbidity and the remaining participants were not identified as having any of the 30 morbidities. We identified a panel of 30 chronic conditions that can be identified from administrative data using validated algorithms, facilitating the study and surveillance of multimorbidity. We encourage other groups to use this scheme, to facilitate comparisons between settings and jurisdictions.

19 May 2009 in BMC Medicine
Verified
Journal Article
Open access
PDF file
TNThe Alberta Kidney Disease Network
The Alberta Kidney Disease Network
MTMarcello Tonelli
Marcello Tonelli
NWNatasha Wiebe
Natasha Wiebe
BHBrenda Hemmelgarn
Brenda Hemmelgarn
SKScott Klarenbach
Scott Klarenbach
JGJohn Gill
John Gill
Hemodialysis patients are at risk for deficiency of essential trace elements and excess of toxic trace elements, both of which can affect health. We conducted a systematic review to summarize existing literature on trace element status in hemodialysis patients.

15 October 2014 in BMC Medicine
Verified
Journal Article
Open access
PDF file
LWLindsey M Warkentin
Lindsey M Warkentin
SMSumit R Majumdar
Sumit R Majumdar
JJJeffrey A Johnson
Jeffrey A Johnson
CACalypse B Agborsangaya
Calypse B Agborsangaya
CRChristian F Rueda-Clausen
Christian F Rueda-Clausen
RPRaj Padwal
Raj Padwal
Guidelines and experts describe 5% to 10% reductions in body weight as `clinically important’; however, it is not clear if 5% to 10% weight reductions correspond to clinically important improvements in health-related quality of life (HRQL). Our objective was to calculate the amount of weight loss required to attain established minimal clinically important differences (MCIDs) in HRQL, measured using three validated instruments. Data from the Alberta Population-based Prospective Evaluation of Quality of Life Outcomes and Economic Impact of Bariatric Surgery (APPLES) study, a population-based, prospective Canadian cohort including 150 wait-listed, 200 medically managed and 150 surgically treated patients were examined. Two-year changes in weight and HRQL measures (Short-Form (SF)-12 physical (PCS; MCID = 5) and mental (MCS; MCID = 5) component summary score, EQ-5D Index (MCID = 0.03) and Visual Analog Scale (VAS; MCID = 10), Impact of Weight on Quality of Life (IWQOL)-Lite total score (MCID = 12)) were calculated. Separate multivariable linear regression models were constructed within medically and surgically treated patients to determine if weight changes achieved HRQL MCIDs. Pooled analysis in all 500 patients was performed to estimate the weight reductions required to achieve the pre-defined MCID for each HRQL instrument. Mean age was 43.7 (SD 9.6) years, 88% were women, 92% were white, and mean initial body mass index was 47.9 (SD 8.1) kg/m2. In surgically treated patients (two-year weight loss = 16%), HRQL MCIDs were reached for all instruments except the SF-12 MCS. In medically managed patients (two-year weight loss = 3%), MCIDs were attained in the EQ-index but not the other instruments. In all patients, percent weight reductions to achieve MCIDs were: 23% (95% confidence interval (CI): 17.5, 32.5) for PCS, 25% (17.5, 40.2) for MCS, 9% (6.2, 15.0) for EQ-Index, 23% (17.3, 36.1) for EQ-VAS, and 17% (14.1, 20.4) for IWQOL-Lite total score. Weight reductions to achieve MCIDs for most HRQL instruments are markedly higher than the conventional threshold of 5% to 10%. Surgical, but not medical treatment, consistently led to clinically important improvements in HRQL over two years. Clinicaltrials.gov NCT00850356 .

19 October 2017 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
DCDavid Collister
David Collister
NPNeesh Pannu
Neesh Pannu
FYFeng Ye
Feng Ye
MJMatthew James
Matthew James
BHBrenda Hemmelgarn
Brenda Hemmelgarn
ONOn Behalf Of The Alberta Kidney Disease Network
On Behalf Of The Alberta Kidney Disease Network
Background and objectives: An understanding of the health care resource use associated with AKI is needed to frame the investment and cost-effectiveness of strategies to prevent AKI and promote kidney recovery. Design, setting, participants, & measurements: We assembled population-based cohort of adults hospitalized in Alberta between November of 2002 and March of 2009 without ESRD or an eGFR<15 ml/min per 1.73 m2. Outpatient serum creatinine measurements 6 months preceding admission defined baseline kidney function, and serum creatinine during the first 14 days of hospitalization defined Acute Kidney Injury Network stage; kidney recovery defined as serum creatinine within 25% of baseline and independence from dialysis was assessed at 90 days after AKI. Health care utilization and costs (in 2015 Canadian dollars) were determined from inpatient, outpatient, and physician claims datasets during the index hospitalization, recovery period (90 days post-AKI assessment), and 3–12 months post-AKI. A fully adjusted generalized linear model regression analysis was used to estimate costs associated with AKI. Results: Of 239,906 hospitalized subjects, 25,495 (10.6%), 4598 (1.9%), 2493 (1.0%), and 670 (0.3%) had Acute Kidney Injury Network stages 1, 2, 3 without dialysis, and 3 with dialysis, respectively. Greater severity of AKI was associated with incremental increases in length of stay (+2.8; 95% confidence interval, 1.4 to 4.3 to +7.4; 95% confidence interval, 7.2 to 7.5 days) and costs (+$3779; 95% confidence interval, $3555 to $4004 to +$18,291; 95% confidence interval, $15,573 to $21,009 Canadian dollars) from admission to recovery assessment (3 months). At months 3–12 postadmission, compared with subjects without AKI, AKI with kidney recovery and AKI without kidney recovery were associated with incremental costs of +$2912–$3231 and +$6035–$8563 Canadian dollars, respectively. The estimated incremental cost of AKI in Canada is estimated to be over $200 million Canadian dollars per year. Conclusions: Severity of AKI, need for dialysis, and lack of kidney recovery are associated with significant health care costs in hospitalized patients and persist a year after admission. Strategies to identify, prevent, and facilitate kidney recovery are needed.

5 March 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
SKS. Klarenbach
S. Klarenbach
JGJ. S. Gill
J. S. Gill
GKG. Knoll
G. Knoll
TCT. Caulfield
T. Caulfield
NBN. Boudville
N. Boudville
FNfor the Donor Nephrectomy Outcomes Research (DONOR) Network
for the Donor Nephrectomy Outcomes Research (DONOR) Network
Some living kidney donors incur economic consequences as a result of donation; however, these costs are poorly quantified. We developed a framework to comprehensively assess economic consequences from the donor perspective including out‐of‐pocket cost, lost wages and home productivity loss. We prospectively enrolled 100 living kidney donors from seven Canadian centers between 2004 and 2008 and collected and valued economic consequences ($CAD 2008) at 3 months and 1 year after donation. Almost all (96%) donors experienced economic consequences, with 94% reporting travel costs and 47% reporting lost pay. The average and median costs of lost pay were $2144 (SD 4167) and $0 (25th–75th percentile 0, 2794), respectively. For other expenses (travel, accommodation, medication and medical), mean and median costs were $1780 (SD 2504) and $821 (25th–75th percentile 242, 2271), respectively. From the donor perspective, mean cost was $3268 (SD 4704); one‐third of donors incurred cost >$3000, and 15% >$8000. The majority of donors (83%) reported inability to perform usual household activities for an average duration of 33 days; 8% reported out‐of‐pocket costs for assistance with these activities. The economic impact of living kidney donation for some individuals is large. We advocate for programs to reimburse living donors for their legitimate costs.

1 September 2009 in Seminars in Nephrology
Verified
Journal Article
Closed access
SKScott Klarenbach
Scott Klarenbach
BMBraden Manns
Braden Manns